Drug recall · June 4, 2025
Theophylline recall
Why: OOS results reported for the Dissolution (by UV) test.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01
- Lots / codes
Lots: 19234121, 19234148, Exp Sep-30-25; Lots 19242881, 19242899, Exp Jun-30-26
- Quantity
- 8,520 100-count bottles
- Company
- Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ
- Distribution
- Nationwide in the USA
- Initiated
- May 15, 2025 · Voluntary: Firm initiated
- Classified
- May 28, 2025
- Reported
- June 4, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Theophylline
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.